Zealand Pharma Stock News

Press release – No. 20 / 2026 Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases Collaboration will combine Zealand Pharma's expertise in metabolic health with Generate's proprietary generative AI platform to create multispecific drug candidates with tailored biological functions Generate w...

Zealand Pharma said on Wednesday its experimental drug helped people who are overweight or ​obese and have type 2 diabetes ‌lose up to 9.2% of their body weight in a mid-stage trial. The Danish company is developing it ​with Roche.

Company announcement – No. 54 / 2026 Zealand Pharma announces positive Phase 2 ZUPREME-2 topline results for amylin analog petrelintide in people with overweight or obesity and type 2 diabetes Petrelintide achieved up to 9.2% mean body weight reduction at week 28 versus 2.0% with placebo At week 28, petrelintide demonstrated a HbA1c reduction of up to 0.65% versus an increase of 0.23% with plac...

Company announcement No. 53 / 2026 Zealand Pharma - Completion of share buy-back program and related transactions (week 40 and 41, 2026) Copenhagen, Denmark, October 5, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no.

Press release – No. 19 / 2026 Zealand Pharma announces opening of new Research Hub in Cambridge, Massachusetts  Builds on the Metabolic Frontier 2030 strategy, advancing its ambition to become a leader in obesity and metabolic health Ribbon-cutting ceremony marks the official opening of the Company's primary U.S. address, expanding Zealand Pharma's global research platform Copenhagen, Denmark, ...

Nearly one in five patients quit Zealand Pharma's late-stage survodutide trial due to ​gastrointestinal side effects caused by the ‌obesity drug, data released on Thursday showed, again raising investor concerns over the high dropout rates.

Company announcement – No. 52 / 2026 Zealand Pharma announces Boehringer Ingelheim's survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes In the SYNCHRONIZE-2 trial, which met its co-primary endpoints, participants achieved significant body weight reduction of up to 13.1% versus 3.1...

Company announcement – No. 51 / 2026 Total number of shares and voting rights in Zealand Pharma as of September 30, 2026 Copenhagen, Denmark, September 30, 2026 – Zealand Pharma A/S (“Zealand Pharma” or "the Company")  (Nasdaq: ZEAL) (CVR-no.